An Open, Randomized, Multicentre Trial to Evaluate Efficacy and Safety of a 24-Week Course of PEG-Interferon Alpha-2b Versus a 12-Week Course of PEG-Interferon Alpha-2b Alone or Plus Ribavirin in Patients With Acute Hepatitis C.

Trial Profile

An Open, Randomized, Multicentre Trial to Evaluate Efficacy and Safety of a 24-Week Course of PEG-Interferon Alpha-2b Versus a 12-Week Course of PEG-Interferon Alpha-2b Alone or Plus Ribavirin in Patients With Acute Hepatitis C.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Jan 2014 Results published in the Hepatology.
    • 30 Jan 2012 Actual patient number changed from 137 to 130 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top